TrialGynecologic oncology2025

A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer.

Stéphanie Gaillard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.